Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial
Clinical Nutrition · 2025-09 · 52 · 17-26
DOI: 10.1016/j.clnu.2025.07.006 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Nutrition, 2025-09. Verfasst von Ignacio Moratilla-Rivera und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Consejo Superior de Investigaciones Científicas …. Hauptthemen laut MEDLINE: Phenylethyl Alcohol, Prediabetic State, Overweight, Dietary Supplements. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
BACKGROUND & AIM: Hydroxytyrosol (HT), an olive-derived phenolic compound, possesses well-known antioxidant and anti-inflammatory properties. While its benefits in healthy individuals and as part of extra virgin olive oil are well studied, its preventive role as a dietary supplement in at-risk populations remains less explored. This study investigates the potential of HT supplementation in preventing aging-related diseases in overweight individuals with prediabetes. METHODS: A randomized, double-blind, placebo-controlled trial was conducted in adults with overweight and prediabetes (40-70 years). For 16 weeks, volunteers consumed either 15 mg of HT or a placebo daily. The primary outcome were oxidized LDL (oxLDL) levels, while secondary outcomes included biochemical and metabolic parameters, oxidative stress and inflammation biomarkers, and lifestyle assessments. Compliance was verified through urinary HT-3'-sulphate levels. RESULTS: A total of 52 participants were recruited and randomized, with 49 completing the study. They were then allocated to either the HT-treated group (n = 24) or the placebo group (n = 25). Compliance was confirmed, as the HT-supplemented group showed increased urinary HT-3'-sulphate levels, whereas the placebo group exhibited a significant decrease (p = 0.039). Compared with placebo, HT supplementation significantly reduced oxLDL levels (p = 0.045), protein carbonyls (p = 0.031), and 8-OHdG (p < 0.01). Additionally, it prevented a decline in total antioxidant status (p < 0.01) and GPx activity (p < 0.01). An anti-inflammatory effect was also observed, with reduced IL-6 levels (p = 0.05). No significant changes were found in lipid profile, anthropometric parameters, or lifestyle factors such as sleep, mental well-being, or physical capacity. No adverse events were observed throughout the intervention. CONCLUSION: Chronic supplementation with 15 mg/day of HT for 16 weeks significantly improved antioxidant and anti-inflammatory status in individuals with overweight and prediabetes, suggesting a potential preventive role against aging-related diseases. REGISTRATION NUMBER OF CLINICAL TRIAL: NCT06295913 (https://clinicaltrials.gov/study/NCT06295913?intr=Hydroxytyrosol&page=2&rank=1).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Consejo Superior de Investigaciones Científicas (CSIC), C/Jose Antonio Novais 6, 28040, Madrid, Spain; Faculty of Biol…
- Department of Metabolism and Nutrition, Institute of Food Science, Technology and Nutrition (ICTAN), Consejo Superior de Investigaciones Científicas (CSIC), C/Jose Antonio Novais 6, 28040, Madrid, Spain; CIBER de Diabet…
- Nutrition and Obesity Group, Department of Pharmacy and Food Science, University of the Basque Country (UPV/EHU) and Lucio Lascaray Research Institute, 01006, Vitoria-Gasteiz, Spain; CIBER de Fisiopatología de la Obesid…
Förderung
- Ministerio de Ciencia, Innovación y Universidades
Zitieren
APA
Moratilla-Rivera, I., Pérez-Jiménez, J., Ramos, S., Portillo, M. P., Martín, M. Á., & Mateos, R. (2025). Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial. Clinical Nutrition, 52, 17-26. https://doi.org/10.1016/j.clnu.2025.07.006
Vancouver
Moratilla-Rivera I, Pérez-Jiménez J, Ramos S, Portillo MP, Martín MÁ, Mateos R. Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial. Clinical Nutrition. 2025;52:17-26. doi:10.1016/j.clnu.2025.07.006
BibTeX
@article{MoratillaRivera2025,
author = {Moratilla-Rivera, Ignacio and Pérez-Jiménez, Jara and Ramos, Sonia and Portillo, María Puy and Martín, María Ángeles and Mateos, Raquel},
title = {Hydroxytyrosol supplementation improves antioxidant and anti-inflammatory status in individuals with overweight and prediabetes: A randomized, double-blind, placebo-controlled parallel trial},
journal = {Clinical Nutrition},
year = {2025},
volume = {52},
pages = {17--26},
doi = {10.1016/j.clnu.2025.07.006}
}
EUVIMED